Morgan Stanley's decision to maintain an Overweight rating on MetLife indicates a positive outlook for the stock. However, the lowering of the price target from $80 to $78 suggests a slightly reduced growth potential. This mixed signal is likely to have a neutral short-term impact on the stock price.